Molecular chaperones contribute to the maintenance of cellular protein homeostasis
through a wide range of mechanisms, including the assistance of de novo protein folding,
the rescue of misfolded proteins, and the prevention of amyloid formation. Chaperones of
the Hsp70 family have a striking capability of disaggregating otherwise irreversible
aggregate structures such as amyloid fibrils that accumulate during the development of
neurodegenerative diseases. However, the mechanisms of this key emerging functionality
remain largely unknown. Here, we bring together microfluidic measurements with kinetic
analysis and show that that the Hsp70 protein heat chock complement Hsc70 together with
its two co-chaperones DnaJB1 and the nucleotide exchange factor Apg2 is able to
completely reverse the aggregation process of alpha-synuclein, associated with Parkinson's
disease, back to its soluble monomeric state. Moreover, we show that this reaction proceeds
with first order kinetics in a process where monomer units are taken off directly from the
fibril ends. Our results demonstrate that all components of the chaperone triad are essential
for fibril disaggregation. Lastly, we quantify the interactions between the three chaperones
as well as between the chaperones and the fibrils in solution, yielding both binding
stoichiometries and dissociation constants. Crucially, we find that the stoichiometry of
Hsc70 binding to fibrils suggests Hsc70 clustering at the fibril ends. Taken together, our
results show that the mechanism of action of the Hsc70-DnaJB1-Apg2 chaperone system
in disaggregating α-synuclein fibrils involves the removal of monomer units without any
intermediate fragmentation steps. These findings are fundamental to our understanding of
the suppression of amyloid proliferation early in life and the natural clearance mechanisms
of fibrillar deposits in Parkinson's disease, and inform on the possibilities and limitations of
this strategy in the development of therapeutics against synucleinopathies and related
neurodegenerative diseases.